New valve device for leaky heart valve under study in europe
NCT ID NCT05820516
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 100 adults with severe tricuspid regurgitation who receive the TricValve implant. Researchers will track survival, heart failure hospitalizations, kidney function, and quality of life for up to one year. The goal is to understand how well the device works and its effects on the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE TRICUSPID VALVE REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliero Universitaria Pisana
RECRUITINGPisa, Pisa, 56124, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.